Daily Stock Analysis, ITCI, Intra-Cellular Therapies Inc, priceseries

Intra-Cellular Therapies Inc. Daily Stock Analysis
Stock Information
Open
12.73
Close
14.15
High
14.35
Low
12.61
Previous Close
12.51
Daily Price Gain
1.64
YTD High
15.00
YTD High Date
Feb 27, 2019
YTD Low
10.34
YTD Low Date
Jun 11, 2019
YTD Price Change
2.63
YTD Gain
22.83%
52 Week High
23.62
52 Week High Date
Sep 26, 2018
52 Week Low
10.21
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-6.24
52 Week Gain
-30.60%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 8. 2017
14.16
Mar 20. 2017
14.88
8 Trading Days
5.06%
Link
LONG
Jun 13. 2017
10.13
Jul 6. 2017
12.28
16 Trading Days
21.18%
Link
LONG
Aug 28. 2017
15.70
Sep 14. 2017
19.67
12 Trading Days
25.31%
Link
LONG
Jan 3. 2018
15.47
Jan 25. 2018
17.98
15 Trading Days
16.21%
Link
LONG
Feb 12. 2018
16.93
Feb 28. 2018
19.42
11 Trading Days
14.73%
Link
LONG
May 11. 2018
20.35
Jun 4. 2018
22.04
15 Trading Days
8.33%
Link
LONG
Jul 5. 2018
18.92
Jul 27. 2018
20.77
16 Trading Days
9.80%
Link
LONG
Jan 4. 2019
11.88
Jan 17. 2019
12.76
9 Trading Days
7.44%
Link
LONG
Feb 1. 2019
12.14
Feb 21. 2019
13.05
13 Trading Days
7.52%
Link
Company Information
Stock Symbol
ITCI
Exchange
NasdaqGS
Company URL
http://www.intracellulartherapies.com
Company Phone
212-923-3344
CEO
Sharon Mates
Headquarters
New York
Business Address
430 EAST 29TH STREET, NEW YORK, NY 10016
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001567514
About

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. Intra-Cellular Therapies was founded by Paul Greengard on August 29, 2013 and is headquartered in New York, NY.

Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.